J&J dumps PhII-ready CD28 au­toim­mune as­set, re­turns rights to French part­ner

J&J’s 5-year ac­quain­tance­ship with OSE Im­munother­a­peu­tics has come to an end as the phar­ma gi­ant de­cid­ed it doesn’t want the CD28 an­tag­o­nist FR104 af­ter all.

The deal ter­mi­na­tion means that Nantes, France-based OSE will once again hold world­wide rights to the as­set — in­clud­ing any new da­ta, IP and reg­u­la­to­ry fil­ings gen­er­at­ed by J&J’s biotech unit Janssen — which is now ready for Phase II test­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.